Surmodics Inc Stock Price, News & Analysis

Surmodics (Nasdaq: SRDX) said the U.S. District Court for the Northern District of Illinois denied the FTC and certain state regulators' request for a preliminary injunction to block the proposed acquisition by an affiliate of GTCR on November 11, 2025. The Merger remains subject to a Temporary Restraining Order that prevents closing before 5:00 p.m. CT on November 17, 2025 and to satisfaction or waiver of customary closing conditions in the merger agreement, including absence of any injunction and no Company Material Adverse Effect. Management described the court ruling as a significant step toward completing the Merger and thanked legal advisors and employees for their work and performance.

Surmodics (Nasdaq: SRDX) reported outcomes from 160 real-world patients in the PROWL registry evaluating the Pounce™ Thrombectomy Platform for infrainguinal limb ischemia; results were presented November 3, 2025.

Key metrics: procedural success 91.7%, device-related major adverse events 0.6%, core-lab TIPI 2-3 flow 94.8%, technical success 83.2%, average device use 24.1 minutes, median 2 passes. 43.1% presented with symptoms >2 weeks; 78.8% required no adjunctive clot therapies. 30-day all-cause outcomes included major amputation 8.1%, target lesion revascularization 7.5%, and death 4.4%.

Surmodics (Nasdaq: SRDX) announced that updated safety and performance data from the PROWL registry — covering 160 patients with symptomatic lower-extremity (infrainguinal) thromboembolic disease treated with the Pounce™ Thrombectomy Platform — will be presented in an industry-sponsored session at the 23rd Annual VIVA Conference.

Presenters Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone will present case insights and real-world clinical outcomes on November 3, 2025 at 3:15 PM PST at Wynn Las Vegas, InnoSphere.

Surmodics (Nasdaq: SRDX) presented a sex-specific analysis of 160 real-world infrainguinal patients from the PROWL registry treated with the Pounce Thrombectomy Platform.

Key results through 30 days: procedural (patient-level) success 94.7% in women vs 89.9% in men (p=0.3765); technical (lesion-level) success 91.4% in women vs 78.3% in men (p=0.0261); core-lab adjudicated thrombus removal complete/substantial ~93.8% women vs 94.3% men; arterial flow (TIPI Grade 2/3) improved in 97.2% women vs 93.4% men. Composite freedom from all-cause MAEs was 73.3% women vs 86.0% men (p=0.0599). The registry includes acute, subacute, and chronic presentations, with ~42–44% presenting >2 weeks of symptoms.

Surmodics (Nasdaq: SRDX) will present sex-specific results from the PROWL registry evaluating the Pounce™ Thrombectomy Platform for non-surgical removal of emboli and thrombi in peripheral arterial vasculature.

The analysis includes 160 patients with symptomatic infrainguinal (lower extremity) vessels. Presentation by Dr. Peter Monteleone is scheduled for October 28, 2025 at 12:40 PM PDT during the 37th Annual TCT Symposium at Moscone Center, Station 3, Halls B-C in San Francisco.

Surmodics (Nasdaq: SRDX) reported Q3 fiscal 2025 results with total revenue of $29.6 million, down 3% year-over-year. The company experienced a GAAP net loss of $(5.3) million, an improvement from $(7.6) million in the prior year period, while Adjusted EBITDA increased to $3.4 million from $1.6 million.

Key highlights include the commercial release of the Pounce XL Thrombectomy System and publication of the TRANSCEND clinical trial demonstrating SurVeil™ DCB's non-inferiority. The company updated its FY2025 guidance, now expecting revenue between $116.5-$118.5 million. The pending acquisition by GTCR continues to face FTC challenges.

Medical Device segment revenue decreased 5% to $22.2 million, while In Vitro Diagnostics revenue grew 6% to $7.4 million. The company maintained a strong balance sheet with $32.7 million in cash and investments.

Surmodics (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies, will release its Q3 fiscal 2025 financial results before market opens on Friday, August 8, 2025. Due to the pending acquisition by GTCR, the company will not host its usual webcast and conference call to discuss the quarterly results.

Surmodics reported Q2 fiscal 2025 results with total revenue of $28.1 million, marking a 12% year-over-year decrease. The company faced a GAAP loss of $(5.2) million, compared to a net income of $0.2 million in the prior year.

Key highlights include:

• Medical Device revenue declined 17% to $20.7 million
• In Vitro Diagnostics revenue grew 3% to $7.4 million
• Successful launch of Pounce XL Thrombectomy System
• Publication of TRANSCEND clinical trial results for SurVeil drug-coated balloon

The company introduced fiscal 2025 guidance, projecting revenue between $114-117 million, representing a 7-10% decrease from 2024. The FTC has issued an administrative complaint regarding the pending GTCR acquisition. Despite challenges, Surmodics maintains focus on strategic initiatives, including expense control and product adoption growth.

Surmodics (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, has announced the scheduled release of its second quarter fiscal 2025 financial results. The results will be made public before market opening on Wednesday, April 30.

Due to the pending acquisition by GTCR, the company will not conduct its usual live webcast and conference call to discuss the quarterly results and accomplishments. This represents a departure from typical earnings release practices, likely due to the ongoing acquisition process.